Vol. XXX, n.5, 2009 ISSN: 0392-2936


european journal
of gynaecological oncology

an International Journal


Founding Editor
A. Onnis
Montréal (Canada)

Editors-in-Chief
M. Marchetti
Montréal (Canada)
P. Bösze
Budapest (Hungary)

Associate Editor
T. Maggino
Padua (Italy)

Assistant Editor
J. Wilson
San Diego - CA (USA)
Editorial Board
Allen H.H., London, Ontario (Canada)
Anteby S.O., Jerusalem (Israel)
Audet-Lapointe P., Montreal (Canada)
Ayhan A., Ankara (Turkey)
Balat O., Graziantep (Turkey)
Ba˘nceanu G., Bucarest (Romania)
Basta A., Krakow (Poland)
Bender H.C., Dusseldorf (Germany)
Benedetti Panici P.L., Rome (Italy)
Charkviani T., Tbilisi (Georgia)
De Oliveira C.F., Coimbra (Portugal)
Dexeus S. Jr., Barcelona (Spain)
Di Paola G.R.,
Buenos Aires (Argentina)
Di Re F., Milan (Italy)
Di Saia P., Orange, CA (USA)
Friedrich M., Hamburg (Germany)
Fuller A.F. Jr., Boston, MA (USA)
Geisler H.E., Indianapolis, IN (USA)
Gerbaulet A., Villejuif (France)
Gorins A., Paris (France)
Heintz A.P.M.,
Utrecht (The Netherlands)
Ioannidou-Mouzaka L.,
Athens (Greece)
Jordan J.A.,
Birmingham, England (UK)
Karseladze A.I., Moscow (Russia)
Klastersky J., Bruxelles (Belgium)
Kubista E., Vienna (Austria)
Maggino T., Padua (Italy)
Markowska J., Poznan (Poland)
Marth C., Innsbruck (Austria)
Massuger Leon F.A.G.,
Nijmegen (The Netherlands)
Menczer J., Savyon (Israel)
Monsonego J., Paris (France)
Pálfalvi L., Budapest, (Hungary)
Pinotti A., São Paulo (Brazil)
Piura B., Beer Sheva (Israel)
Piver S.M., Buffalo, NY (USA)
Rakar S., Ljubljana (Slovenia)
Raju K.S., London, England (UK)
Shepherd J.H.,
London, England (UK)
Stelmachów J., Warsaw (Poland)
Tjalma W., Antwerpen (Belgium)
Ungár L., Budapest (Hungary)
Vermorken J.B., Edegem (Belgium)
Wang P.-H., Taipei (Taiwan)
Winter R., Graz (Austria)
Yokoyama Y., Hirosaki (Japan)

Publishing Organization (M. Morsani):
I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc - Apt # 212 - Montréal, Qué. H3W 2H3 (Canada)
Tel. +514-4893242 - Fax +514-4854513 - E-mail: canlux@mgroup-online.com - www.irog.net

Editorial Office (M. Critelli):
Galleria Storione, 2/A - 35123 Padua (Italy) - Tel. (39) 049 8756900 - Fax (39) 049 8752018

 

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed works in the fields of female genital cancers and related subjects and also proceedings of gynecologic oncology society meetings all over the world. The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/ Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

 

European Journal of Gynaecological Oncology
www.irog.net


General Information

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed work, preferably brief reports, in the fields of female genital cancers and related subjects – prevention, early detection, epidemiology, pathology, diagnosis, management – and also proceedings of Gynaecologic Oncology Society meetings all over the world.

The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE,
EMBASE/ Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

AIMS AND SCOPE
The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is dedicated to publishing editorial articles in the “Distin-guished Expert Series” and original research papers, case reports, letters to the Editor, book reviews and newsletters.

The Journal was founded in 1980 – the second gynaecologic oncology hyperspecialization journal in the world. Its aim is the dif-fusion of scientific, clinical and practical progress and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists and so on.

ANNOUNCEMENTS regarding meetings, postgraduate courses and symposia will be accepted 6 months before publication and will be published free of charge.
BOOK SAMPLES for review should be sent to the Editorial offices in Montréal or in Padova.
COPYRIGHT: the Journal has been registered with the Copyright Clearance Center, Inc. Reproductions are not allowed without the written consent of the Publisher. All photocopy fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA stating the ISSN number, the volume and the first and last page numbers of each article copied.
ADVERTISING INFORMATION: advertising orders and inquiries may be sent to: I.R.O.G. CANADA Inc., Publisher, 4900 Côte St. Luc, Apt. 212, Montréal (Quebec) Canada H3W 2HS, Tél. 514.4893242-4893640 - Fax 514.4854513 - E-mail: canlux@mgroup-online.com - www.irog.net
RESPONSIBILITY: although every effort is made by the editorial staff and the printer to eliminate misleading or inaccurate infor-mation, the publisher accepts no responsibility for the consequences of faultful or incorrect information. The authors recognize that the editor and publisher have no responsibility and are indemnified against any liability or claim that may result from the publication of misleading or incorrect data.


SUBSCRIPTION INFORMATION
The Journal is published bimonthly (January, March, May, July, September and November); one volume per year. Subscriptions start from January and are automatically renewed if not cancelled by the end of September.

Subscriptions include six issues per year plus supplements, monographs and all official communications of Meetings, Courses, Symposia and all scientific activities of Gynaecologic Oncology Societies all over the world.

Subscriptions are entered with prepayment only. The annual subscription is $390 US for Institutions, $200 US for Individuals. For airmail add $30, for receipt add $10 US. Single copy prepaid cost $95 US.

Send subscription requests with cheque or credit card payment (Amex - Visa - Diner’s - Master Card) to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, Montréal, Québec H3W 2H3 Canada. Only US Funds are accepted. No bank transfers.

Claims for missing issues can be honoured up to six months. Changes of address: allow six weeks for all changes to become effec-tive. All communications should include both old and new addresses (with postal codes) – better if accompanied by a mailing label from a recent issue – and should be sent to the printer: La Garangola, Via E. Dalla Costa 6, 35129 Padova (Italy) or by Fax +39.049.7806580. Claims should be made within six months of publication date.

Duplicate copies will not be sent to replace those undelivered through failure to notify of change of address.

Single copies and back issue and volume information is available from the printer, La Garangola, Padova, Tel. +39.049.8075557, Fax +39.049.7806580. Certain back issues may only be available as photocopies of the originals.

All other business correspondence including orders for offprints and advertising space and any communication and requests should be addressed to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, MONTRÉAL, QUÉBEC H3W 2H3 (Canada), tel. (514) 4893242, fax (514) 4854513.

IN ALL LEGAL MATTERS THE COURT OF MONTREAL IS COMPETENT

 

European Journal of Gynaecological Oncology
www.irog.net


Instructions to Authors

SUBMISSION OF MANUSCRIPTS
Papers should be submitted to A. ONNIS Editor-in-Chief of the EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 4900 Côte St. Luc, Apt. 212 MONTREAL, QUÉBEC H3W 2H3 (Canada) - Tel. +514-4893242 - Fax +514-4854513, or Galleria Sto-rione 2/A - 35123 PADOVA (Italy) - Fax +39-049-8752018.

Editorial articles for publication in the “Distinguished Expert Series” should be submitted to P. Bösze, Editor-in-Chief of this section, Department of Gynecology, Saint Stephan Hospital, 1096 Budapest, Nagyvárad tér 1, Telephone (36-1) 275 2172, Fax (36-1)
275 2172, E-mail: bosze@axelero.hu

When a manuscript is submitted, an acknowledgement card is sent to the corresponding author within two or three weeks.

Submitted papers are reviewed by the Editor-in-Chief and his Peer Referees. Authors may be required to modify the manuscript according to the reviewers’ suggestions.

Manuscripts accepted for publication will be copyedited by the editorial staff for typographical and grammatical mistakes and to guarantee clarity and conciseness.

Publication time will be the shortest possible based on scientific and publishing needs. Manuscripts submitted for publi-cation cannot be returned.

Published papers will become property of the Journal and copyrighted under I.R.O.G. CANADA Inc.

After six months no grievances will be accepted regarding published articles.

All statements are the responsibility of the authors. Product dosages, indications and methods referred to in the papers reflect the author’s experience. No responsibility is assumed by the Editor-in-Chief or the Publisher for any damage from use of any products, operation methods or instructions contained in the published materials.

Trade names, trademarks, etc. are protected by the law and regulations. The Editor-in-Chief and the Publisher cannot accept any legal responsibility for any errors or omissions that may be made in press, particularly for information about drug dosage and appli-cation thereof contained in the Journal. Consult the prescribing information before administering any drug.

MANUSCRIPT REQUIREMENTS
The Journal follows the “Uniform requirements for manuscripts submitted to biomedical journals” published in the New England Journal of Medicine 1991, 324, 424-8 and in the British Medical Journal 1991, 302.

Three manuscripts, typed and double spaced should be submitted with an electronic disk, formatted in Word for Macintosh or Windows, version 6.0. Manuscripts without an electronic disk will not be accepted. A cover letter signed by all authors must state that all authors who have participated in the work take responsibility for the manuscript which has never been pub lished or submitted for publication elsewhere. Without a cover letter the publication will not be possible. Name, address and phone/fax numbers of the Corresponding Author, responsible for revision and approval of the proofs, should be indicated. Full-length articles should not exceed 8 printed pages including tables and references.

After the title page (full title and names of authors, institutions, eventual acknowledgement for financial support, running title of no more than 60 characters or spaces), original works should be arranged in the conventional order: Summary (purpose of investiga-tion, methods, results, conclusion - about 150 words), Key words, Content (a 20-word summary), Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgement (if any), References, Tables, Legends.

Authors should supply a complete address for reprint requests.

In the text only standard abbreviations can be used and must be avoided in the title. The full term for which an abbreviation stands should precede its first use in the summary and text unless it is a standard unit of measurement.

Authors must give their complete professional identifications and affiliations, including all academic titles and positions.

Letters to the editor should be brief (500 words or less) and offer objective, constructive and educational criticism of published material. The editor reserves the right to publish.

Figures: Two original copies (not negatives) of each figure are requested. Each figure should have a label on the back indicating its number, author’s name and top of the figure. Do not write on the back of the figures and do not mount them on cardboard. If sending colour pictures advise if they must be printed in colour or black and white (colour costs ten times more).

Legends should be typed on a separate page with Arabic numerals corresponding to the illustrations.

Tables should be titled, typed in double space on separate pages and numbered in Arabic numerals in the order of their first cita-tion
in the text. Do not use internal rules. Only standard, universally understood abbreviations should be used.

References should be numbered consecutively in the order in which they are first mentioned in the text. Identify references in the text, tables, and legends by Arabic numerals in parentheses.

Use the style of the examples below, which are based with slight modifications on the format used by the U.S. National Library of Medicine in Index Medicus. The titles of journals should be abbreviated according to the style used in Index Medicus.

References must be verified by the Author(s) against the original documents.

Examples of correct forms of references are given below:

Articles in Journals: Authors’ surname and initials (if more than six names, give six followed by “et al.”), Title, Abbreviated Journal Title, Year of Publication, Volume, Issue and first page.

Books: Authors’ surname and initials, title of the book and title of chapter, in: Title, Editor(s), Place, Publisher, Year, Page.

Acknowledgments
will be limited to appropriate professionals who were contributors to the paper.

PROOFS revised by the editorial staff will be sent to the corresponding author and should be checked and returned within ten days. The corresponding author is responsible for detecting typesetting errors. After this deadline the proofs will be considered approved. Only essential corrections should be made; extensive changes will be charged to the authors.

BUSINESS MATTERS
The Journal has no commercial advertisements.

Authors will be expected to contribute to the printing expenses, tables, figures and postage. For every published article a copy of the Journal will be provided free of charge. Only payments in US dollars will be accepted. No bank transfers.

Reprints should be requested with the form enclosed with the acceptance letter. No free reprints will be supplied.



© By I.R.O.G. CANADA INC. - Publisher - Editorial office 4900 Côte St. Luc - Apt. 212 - Montréal Québec H3W 2H3 (Canada) - Tel. (514) 4893242-4893640 - Fax (514) 4854513 - Printed in Italy by “La Garangola” - Via E. Dalla Costa, 6 - 35129 Padua (Italy) - Responsible Director: Prof. Antonio Onnis M.D. - Authorization of Padua’s Court n. 633 - 28-6-1979
   
European Journal of Gynaecological Oncology - Vol. XXX, n.5, 2009
 
   
CONTENTS  
In Memoriam: Antonio Onnis 469
DISTINGUISHED EXPERT SERIES  
Diagnosis and treatment of borderline ovarian neoplasms “the state of the art” 471
C. Tropé, B. Davidson, T. Paulsen, V.M. Abeler, J. Kaern - Oslo, NORWAY
An up-date on serous and mucinous ovarian borderline tumors – survival data and treatment options. A review of the literature.
 
 
REVIEW ARTICLE  
Management of advanced stage uterine sarcomas: A bone of contention 483
F. Zagouri, H. Linardou, A.M. Dimopoulos, C.A. Papadimitriou - Athens, GREECE
Advanced stage of uterine sarcomas constitutes a rare heterogeneous group of neoplasms. The different pathological subtypes demand a tailored approach.
 
 
ORIGINAL ARTICLES  
Patterns of care for the initial management of cervical cancer in Ontario 493
L. Elit, S. Schultz, R. Prysbysz, L. Barbera, R. Saskin, N. Gunraj, A.S. Wilton, D. Urbach, M. Simunovic - Toronto, CANADA
An evaluation of operative services provided for cervical cancer in Ontario.
 
Can routine gynecologic examination contribute to the diagnosis of cervical involvement by primary endometrial cancer? 497
G. Pristauz, R. Winter, E. Fischerauer, J. Haas, V. Bjelic-Radisic, A.A. Bader, E. Petru - Graz, AUSTRIA
Pap smears, colposcopy, cervical palpation and rectal parametrial examination may be useful to preoperatively detect cervical involvement by primary endometrial cancer.
 
Assessment of proliferating activity in Paget’s disease of the nipple by double stain immunohistochemistry 500
F. Buxant, I. Fayt, J.C. Noel - Brussels, BELGIUM
Paget’s disease and underlying intraductal carconomas share a close proliferating activity.
 
Patterns of care in the initial management of women with vulvar cancers in Ontario 503
L. Elit, S. Schultz, R. Prysbysz, L. Barbera, R. Saskin, N. Gunraj, A.S. Wilton, M. Simunovic, D. Urbach - Toronto, CANADA
An evaluation of operative services provided for vulvar cancer in Ontario.
 
The role of sonography in the diagnosis of cystic lesions of the breast 506
M. Bilali, E.E. Lagoudianakis, P. Peitsidis, D. Grosomanidis, A. Papadima, N. Koronakis, J. Chrysikos, D. Tsekouras, S. Nakos, V. Katergiannakis, A. Manouras - Athens, GREECE
Ultrasound examination for palpable cystic breast lesions is especially useful in young women and improves the accuracy of mammography.
 
Histamine and its metabolizing enzymes in tissues of primary ductal breast cancer 509
J. von Mach-Szczypin ´ski, S. Stanosz, K. Sieja, M. Stanosz - Szczecin, POLAND
Increased histamine in ductal breast cancer tissues may be connected with disturbances of balance between synthesis and enzymatic activation of histamine.
 
Cytopathological screening in indigenous women from Parque Indigena do Xingu 512

N.M. de Gois Speck, E.R. Pereira, M. Schaper, D. Rodrigues, P. Almeida, C.R. Sakano, J.C.L. Ribalta - São Paulo, BRAZIL
The coverage index of cervical lesion screening in indigenous women from the Parque Indigena do Xingu has been high.

 
Expression of tubulin, p53, Ki67, receptors for estrogen, and progesterone in endometrial cancer 514
C. Zhu, J. Luo, H. Shi, X, Xie, Z, Ding - Hangzhou, CHINA
Expression of class III β-tubulin in normal endometrium and endometrial carcinoma was investigated.
 
Elevated blood plasma concentrations of active ghrelin and obestatin in benign ovarian neoplasms and ovarian cancers 518
A. Markowska, A. Ziókowska, K. Jaszczynska-Nowinka, R. Madry, L.K. Malendowicz - Poznan, POLAND
Concentrations of active ghrelin and obestatin in the peripheral blood of both patients with benign ovarian tumours and those with ovarian cancer were higher than those in the control group.
 
Effect of intratumoral lymphocyte density on the disease-free survival and overall survival in malignant epithelial tumors of the ovary 523
Y. Do gan, G. Erdogan, H.E. Pestereli, B. Tırak, S ¸. Karaveli - Antalya, TURKEY
No significant relations were found between VEGF expression and presence of intratumoral T lymphocytes and clinico-patho-logical parameters in malignant epithelial ovarian tumors.
 
Mutational analysis of BRCA1 and BRCA2 genes in Mexican breast cancer patients 527
S. Vidal-Millán, L. Taja-Chayeb, O. Gutiérrez-Hernández, M.T. Ramírez Ugalde, C. Robles-Vidal, E. Bargallo-Rocha, A. Mohar-Betancourt, A. Dueñas-González - Mexico, MEXICO
Description of BRCA1 and BRCA2 mutation profiles in Mexican breast cancer patients through DHPLC and sequencing analyses.
 
Cox-2 immunohistochemical expression in epithelial ovarian carcinoma and platin sensitivity 531
J. Menczer, L. Schreiber, V. Kravtsov, E. Berger, A. Golan, T. Levy - Tel Aviv, ISRAEL
COX-2 expression in epithelial ovarian carcinoma is not associated with platin sensitivity and survival.
 
Pelvic lymphadenectomy in endometrial cancer: our current experience 536
T.S. Patrelli, R. Berretta, M. Rolla, F. Vandi, G. Capobianco, D. Gramellini, A. Bacchi Modena, G.B. Nardelli - Sassari, ITALY
Pelivc lymphadenectomy in the surgical staging of endometrial cancer reduces the need of postoperative therapy without causing surgical complications.
 
Small cell carcinoma of the uterine cervix: clinicopathologic study of 20 cases in a single center 539
Y.M. Kim, M.H. Jung, D.Y. Kim, J.H. Kim, Y.T. Kim, J.H. Nam - Seoul, KOREA
Advanced FIGO stage and tumor mass size are poor prognostic factors for overall survival of SCCUC.
 
What is the diagnostic value of nipple discharge cytology and galactography in detecting duct pathology? 543
M.J. Carvalho, M. Dias, N. Gonçalo, G. Fernandes, V. Rodrigues, C.F. de Oliveira - Coimbra, PORTUGAL
Diagnostic value of nipple discharge cytology and galactography to determine the etiological diagnosis of nipple discharge.
 
Dosimetric comparison of intensity modulated pelvic radiotherapy with 3D conformal radiotherapy in patients with gynecologic malignancies 547
S. Igdem, T. Ercan, G. Alço, F. Zengin, R. Özgüles ¸ , G. Geceer, S. Okkan, A. Öber, S. Turkan - Istanbul, TURKEY
Pelvic IMRT significantly reduces the volume of normal tissues irradiated to high doses and has the potential to reduce treatment-related morbidity.
 
The role of endothelin-1 and its correlation with CA125 levels, grayscale ultrasonography and Doppler findings in differential diagnoses of ovarian tumors 552
R. Moszynski, D. Szpurek,S. Michalak, S. Szubert, S. Sajdak - Poznan, POLAND
Endothelin-1 as a new biomarker for predicting ovarian cancer is not satisfying, but its correlation with Doppler parameters is very interesting and the role of endothelin-1 in angiogenesis should be studied.
 
A perspective study on correlation between HPV DNA and lymph nodes in surgically treated cervical carcinoma patients. Preliminary data 557
M. Rolla, R. Berretta, T.S. Patrelli, C. Merisio, D. Gramellini, G.M. Fadda, A. Bacchi Modena, G.B. Nardelli Parma, ITALY
A correlation was found between HPV DNA lymph nodes researched with an innovative technique and lymph node metastases.
 
 
BRIEF COMMUNICATION  
Secular trends in ovarian cancer admissions to a large general hospital during the period 2000-2007 562
M. Dowlut, A. Natalwala, H. Uppal, R. Potluri - London, UK
Information on ethnic variations and length of hospitalization for patients affected by ovarian cancer.
 
 
CASE REPORTS  
Malignant transformation of extragonadal endometriosis: a case report 563
W.C. Wu, M.W. Hsiao, J.C. Ye, Y.C. Hung, W.C. Chang - Taichung, TAIWAN
A rare case of endometrioid adenocarcinoma with a clear transition zone from endometriosis to adenocarcinoma in a 39-year-old is presented.
 
Paraovarian leiomyosarcoma with scalp metastasis: a case report 566
N. Sultana, D.P. Pikaart, S. Ahmad, S.A. DeNardis, N.J. Finkler - Orlando, FL (USA)
An unusual case of paraovarian leiomyosarcoma with scalp metastasis is reported. Post-surgery/chemotherapy, the patient is on palliative taxotere/gemcitabine and doing well.
 
Fallopian tube cancer presenting as inflammatory breast carcinoma: report of a case and review of the literature 568
K. Papakonstantinou, A. Antoniou, K. Palialexis, E. Politi, E. Karvouni, S. Fotiou - Athens, GREECE
Description of the imaging, clinical and pathological findings of a case of papillary serous carcinoma of the fallopian tube with metastases to the breast, axillary and neck lymph nodes in a 56-year-old woman.
 
Two cases of metachronic tumours: cancers of the ovary and endometrium in young women. Case presentation and review 572
A. Markowska, P. Puacz, J. Markowska, J. Bre ˛borowicz, D. Godlewski, J. Lubin - Poznan, POLAND
Manifestation of metachronic cancers – both ovarian and endometrial cancers – before the age of 40 is of casuistic interest. Two cases of metachronic cancers are presented.
 
Primary clear cell carcinoma of the peritoneum: report of two cases and a review of the literature 575
M. Takano, T. Yoshokawa, M. Kato, S. Aida, T. Goto, K. Furuya, Y. Kikuchi - Tokorozawa, JAPAN
Two cases of clear cell carcinoma derived from peritoneum origin are presented with a review of the literature.
 
An incidental peritoneal serous borderline tumor during laparoscopy for endometriosis 579
A. Tinelli, A. Malvasi, M. Pellegrino - Lecce, ITALY
The laparoscopic management of a case of primary peritoneal serous borderline tumor is presented.
 
Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with advanced ovarian cancer 583
H. Yoshida, T. Sumi, K. Abe, O. Ishiko - Osaka, JAPAN
Pharmacokinetic analysis of paclitaxel and carboplatin suggests an optimal method to perform chemotherapy in a hemodialysis patient with ovarian cancer.
 
Intravascular T-cell lymphoma of the vulva, CD30 positive: a case report 586
A. Zizi-Sermpetzoglou, N. Petrakopoulou, N. Tepelenis, V. Savvaidou, T. Vasilakaki - Pireaus, Greece
A case of a 48-year-old woman with intravascular lymphoma of the vulva is presented.
 
Favorable effects of long-term therapy with gonadoliberin analogues in three patients with advanced and recurrent ovarian cancer 589
A. Chudecka-Gaz, I. Rzepka-Górska - Szczecin, POLAND
Description of the long-term survival of women with advanced and recurrent ovarian cancer who used GnRH analogs in adjuvant treatment.
 
Multiple uterine angioleiomyomas mimicking an ovarian neoplasm: a case report 592
S. Hakverdi, K. Dolapçioglu, A. Güngören, M. Yaldiz, A.U. Hakverdi - Antakya, TURKEY
Uterine angioleiomyoma may mimic an ovarian neoplasm. Angiomyomectomy with simple hysterectomy is an effective treatment.
 
Retroperitoneal ancient schwannoma presenting as an ovarian tumor in a patient with uterine cancer. A case report 595
K. Bakalianou, A. Liapis, N. Salakos, C. Iavazzo, M. Tsantopoulos, A. Kondi-Pafiti - Athens, GREECE
A case of a retroperitoneal ancient schwannoma – symptoms, ultrasound/CT findings, treatment and histopathological characteristics are described.
 
Primary adenocarcinoma of the fallopian tube as an incidental finding during surgery in a post-menopausal patient with unspecific pelvic pain 597
L.G.O. Brito, H.R.C. Marana, J.M. de Andrade, P.M. de Paula Philbert, D.G. Tiezzi, F.E. Zola - São Paulo, BRAZIL
A case of fallopian tube cancer was diagnosed as an incidental finding during surgery.